The one therapy available for sufferers with leprechaunism thus far is recombinant IGF1, aiming to avoid compensatory hyperinsulinemia (23). IGF has in regards to the six% in the glucose-lowering action impact of insulin and it has a similar structure to it, therefore it is ready to bind to insulin receptors triggering peripheral glucose uptake and